NCT04370574 Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology
| NCT ID | NCT04370574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Pancreatic Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-01-14 |
| Primary Completion | 2021-01-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2021-01-14 with a primary completion date of 2021-01-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) remains among cancers with a very poor prognosis (1-year survival \<20%). Endoscopic ultrasound with fine needle aspiration (EUS/FNA) is the common examination for all patients with suspicious pancreatic mass. A method was recently developed : it preserves the sanitary sample, named EXPEL, which allows standard pathology examination and OMICS analyzes from the "rinse" liquid. After EUS/FNA in clinical practice, the content of the needle is rinsed in CytoLyt® preservative solution. After cytofiltration, this liquid is systematically discarded. Based on the EXPEL concept, we hypothesise that this all-patients inclusive approach ("Modified EXPEL" procedure) combined with the methodology to access proteomic and metabolomics information in these original samples will allow us to identify a series of clinically useful marker signatures that will ultimately be measurable, non-invasively, in the patient blood.
Eligibility Criteria
Inclusion Criteria: * Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy Exclusion Criteria: * Vulberable person according to L1121-6 of Public health reglementation in France * Pregnant women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04370574 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04370574 currently recruiting?
Yes, NCT04370574 is actively recruiting participants. Contact the research team at fr-souche@chu-montpellier.fr for enrollment information.
Where is the NCT04370574 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT04370574 clinical trial?
NCT04370574 is sponsored by University Hospital, Montpellier. The trial plans to enroll 200 participants.